Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
CRDF Stock Chart & Stats
$2.88
-$0.21(-4.99%)
At close: 4:00 PM EST
$2.88
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.90 - $4.99
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.02M
Market Cap
$194.00M
Enterprise ValueN/A
Total Cash (Recent Filing)$60.59M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 26, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding67,360,565
10 Day Avg. Volume955,413
30 Day Avg. Volume1,020,342
Financial Highlights & Ratios
PEG Ratio-2.12
Price to Book (P/B)2.49
Price to Sales (P/S)302.78
P/FCF Ratio-5.47
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$13.67Price Target Upside374.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$366.11K
Bulls Say, Bears Say
Bulls Say
Efficacy SignalCRDF-004 reported a higher confirmed overall response rate with onvansertib added to standard care, indicating meaningful additive activity against metastatic colorectal cancer.
Registrational StrategyManagement pursuit of a registrational Phase III trial (CRDF-005) signals intent to seek regulatory approval and could establish a clear path to commercialization if trial endpoints are met.
Response Confirmation UpsideA larger pool of unconfirmed responses with onvansertib suggests additional responses may convert to confirmed responses with further follow-up, potentially strengthening the drug's clinical profile.
Bears Say
Comparator Validity ConcernConcern that the control arm may have underperformed could complicate interpretation of efficacy differences and invite closer regulatory or advisory scrutiny.
Funding And Dilution RiskRequirement for additional capital to conduct a pivotal Phase III raises dilution and execution risk if external financing terms are unfavorable or fundraising is delayed.
Potential Trial FailureRisk that CRDF-004 or subsequent studies produce negative or weaker-than-expected results could materially weaken the compound's outlook and investor confidence.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.90 and its highest was $4.99 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $194.00M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 38 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.035.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 67,360,565 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -2.667%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (374.65% Upside)
$13.67 (374.65% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 172.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.29%
12-Months-Change
Fundamentals
Return on Equity
-102.71%
Trailing 12-Months
Asset Growth
1.41%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$13.67
▲(374.65% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
4.37% Insiders
7.31% Mutual Funds
1.12% Other Institutional Investors
78.89% Public Companies and Individual Investors